Pennsylvania is currently home to 3298 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
CD123 Redirected T Cells for AML in Pediatric Subjects
NCT04678336
Recruiting
Phase 1 open-label study to evaluate the safety of intravenously administered, lentivirally transduced T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains in pediatric subjects with relapsed/refractory Acute Myeloid Leukemia (AML).
Gender:
ALL
Ages:
Between 1 year and 29 years
Trial Updated:
02/25/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Pediatric, Acute Myeloid Leukemia, Refractory
Register for Updates
HeartStart FRx Defibrillator Event Registry
NCT04250857
Recruiting
This post market clinical follow-up study is a multi-center, non-randomized, unblinded, observational registry of the performance of the FRx Automated external defibrillator (AED) used in conjunction with electrodes with or without use of the infant/child key. The registry is focused only on on post-event data collection and does not prescribe any device usage. This registry has several safeguards in place to prevent against selections bias, including enrollment of all participants who have pads... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/25/2025
Locations: Philips, Monroeville, Pennsylvania
Conditions: Sudden Cardiac Arrest
Register for Updates
Amplatzer Amulet LAAO Vs. NOAC
NCT04226547
Recruiting
The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. The clinical investigation is a prospective, randomized, multicenter active control worldwide trial. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device ("Device Group") and a commercially available NOAC medication ("Cont... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Pinnacle Health System, Harrisburg, Pennsylvania
Conditions: Atrial Fibrillation, Stroke, Bleeding
Register for Updates
The Radiation Oncology Registry and Biosample Repository
NCT01577251
Recruiting
The goal of this study is to establish a registry and biosample repository (defined as blood, urine, and tumor specimens) in patients with a cancer and/or benign tumor diagnosis undergoing radiotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Lancaster General Hospital, Lancaster, Pennsylvania
Conditions: Neoplasia
Register for Updates
Ex Onc SLED: a Study Utilizing a Weighted Sled for Horizontal Resistance Training
NCT06610396
Recruiting
This protocol seeks to analyze patient adherence and outcomes after monitored exercise sessions utilizing primarily weighted sled pushes and pulls for linearly progressed resistance training of individuals who have been diagnosed with cancer.
Gender:
ALL
Ages:
Between 20 years and 89 years
Trial Updated:
02/24/2025
Locations: Allegheny General Hospital, Pittsburgh, Pennsylvania
Conditions: Cancer
Register for Updates
Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC
NCT05669846
Recruiting
This study is to determine if Healthy Donor FMT (hdFMT) improves the body's ability to fight cancer in patients with relapsed/refractory PD-L1 Positive NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Non Small Cell Lung Cancer
Register for Updates
Enfortumab Vedotin and Pembrolizumab in People with Bladder Cancer
NCT05239624
Recruiting
This study will test whether enfortumab vedotin combined with pembrolizumab is an effective treatment for people with bladder cancer (urothelial carcinoma) involving the lymph nodes who are going to have surgery to remove their cancer (cystectomy). The researchers will look at whether treatment with enfortumab vedotin and pembrolizumab before surgery can get rid of cancer within the lymph nodes. They will also try to find out if this combination of drugs is effective at shrinking participants' c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: Lehigh Valley Health Network (Data Collection Only), Allentown, Pennsylvania
Conditions: Urothelial Carcinoma
Register for Updates
Pediatric Post-Approval Registry
NCT04457154
Recruiting
This registry is a prospective, multi-center, single-arm study of pediatric subjects (ages 18-21 years) who are undergoing implant of the Inspire Upper Airway Stimulation (UAS) System for the treatment of moderate or severe obstructive sleep apnea (OSA). Implanted subjects will be followed for 5 years post-implant.
Gender:
ALL
Ages:
Between 18 years and 21 years
Trial Updated:
02/24/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Obstructive Sleep Apnea
Register for Updates
Autoimmunity After Checkpoint Blockade
NCT04119713
Recruiting
The purpose of this study is to better understand how the treatment of cancer with immune checkpoint inhibitors (ICI) leads to the development of autoimmunity. Specifically, we wish to understand the genetics and immune system features that cause a subset of cancer patients treated with checkpoint inhibitor therapy to develop an immune-related adverse event (irAE).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: University of Pennsylvania - Abramson Cancer Center, Philadelphia, Pennsylvania
Conditions: Autoimmunity, Cancer, Immunotoxicity, Oncology
Register for Updates
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
NCT03970096
Recruiting
This phase II trial investigates two strategies and how well they work for the reduction of graft versus host disease in patients with acute leukemia or MDS in remission. Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cell... Read More
Gender:
ALL
Ages:
Between 1 year and 60 years
Trial Updated:
02/24/2025
Locations: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
Register for Updates
Study of the Research Medicine CIN-103 in Adults with Irritable Bowel Syndrome with Predominant Diarrhea (IBS-D).
NCT06153420
Recruiting
The goal of this clinical trial is to evaluate if the study drug, CIN-103, can help reduce the symptoms associated with irritable bowel syndrome with predominant diarrhea (IBS-D) in adult patients. The main questions it aims to answer are: * To evaluate the efficacy of CIN-103 on symptoms of IBS-D when given to patients with IBS-D compared to a placebo. * To evaluate the safety and tolerability of CIN-103 when given to patients with IBS-D compared to a placebo Participants will attend the foll... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Susquehanna Research Group, LLC, Harrisburg, Pennsylvania
Conditions: Irritable Bowel Syndrome With Diarrhea
Register for Updates
Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects with an IPAA (PROF)
NCT05938465
Recruiting
The aim of this study is to assess the safety and preliminary efficacy of treatment with EXE-346, a live biotherapeutic, which may reduce bowel movement frequency in patients with an ileal pouch-anal anastomosis (IPAA) and lead to a higher quality of life.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Penn State Health (Milton S. Hershey Medical Center), Hershey, Pennsylvania
Conditions: Ileal Pouch
Register for Updates